Immunoproteasome: A key component of the cellular stress response
免疫蛋白酶体:细胞应激反应的关键组成部分
基本信息
- 批准号:7510560
- 负责人:
- 金额:$ 14.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-15 至 2010-08-31
- 项目状态:已结题
- 来源:
- 关键词:Age of OnsetAntigen PresentationApoptoticAtrophicAttenuatedBiochemistryBiological ModelsBiologyBrainCatalytic DomainCell DeathCell LineCell NucleusCell SurvivalCellsCellular StressCellular Stress ResponseCellular biologyChemicalsChronic stressCollaborationsConditionCultured CellsDiseaseDisease ProgressionEndoplasmic ReticulumEpithelial CellsExhibitsExposure toHalf-LifeHindlimbImmuneInjuryKnockout MiceLegitimacyModificationMolecular ChaperonesMolecular GeneticsMusMuscleMuscle functionMuscular AtrophyMyosin ATPaseNatureOxidative StressPeptidesPhysiologyPlayPredispositionProtein IsoformsProteinsResearchResearch ProposalsRetinaRoleSignal TransductionSkeletal MuscleStressSystemTechniquesTestingTissuesToxic effectTransgenic MiceTunicamycinUp-RegulationWorkataxin-1cytotoxicimmune functionimmunogenicin vitro Modelinjuredlensmulticatalytic endopeptidase complexmutantnoveloxidationpolyglutamineprotein aggregateprotein degradationprotein misfoldingresearch studyresponsestressortranscription factor
项目摘要
DESCRIPTION (provided by applicant): The proteasome plays a central role in maintaining cell viability in response to stressors, such as protein overload or endoplasmic reticulum (ER) stress, by regulating signal transduction that promotes cell survival (i.e., NF-?B) and degrading potentially cytotoxic proteins (i.e., defective ribosomal products or DRiPs). The proposed work investigates the interplay between specific stressors (Protein Overload and ER Stress) and the immunoproteasome by defining conditions that induce immunoproteasome expression and testing specific hypotheses regarding immunoproteasomes role in responding to cellular stress. While its role in generating immunogenic peptides for antigen presentation has been clearly established, the expression of immunoproteasome subunits in non-inflammed immune-privileged tissue such as retina and brain implies other non-immune functions are possible. Notably, the upregulation of immunoproteasome in diseased retina and brain suggests it responds to challenges that induce stress and injury. The central hypothesis is that the immunoproteasome is a key component of the cellular response to stress. We have made several predictions that can be experimentally tested using techniques and strategies already familiar to our lab and the labs of our collaborators using knock-out mice lacking two (lmp7-/-/mecl-1-/-, L7M1) catalytic subunits of the immunoproteasome and conditional SCA1 transgenic mice expressing either the WT [30Q] or the mutant [82Q] ataxin-1 protein. Cell lines generated from WT and L7M1 mice and transfected with either the WT [30Q] or mutant [82Q] ataxin protein provide excellent in vitro model systems for testing our hypotheses. (Aim 1) Hypothesis: Immunoproteasome is required for effective muscle remodeling. Muscle remodeling will be induced by hindlimb unweighting WT and L7M1 mice to test if immunoproteasome (a) helps maintain muscle function during muscle remodeling, (b) provides protection from cellular damage, and (c) is directly involved in muscle remodeling. (Aim 2) Hypothesis: Immunoproteasome helps protect cells from the toxic effects of misfolded proteins. Using the conditional SCA1 transgenic mouse and cultured cells (WT and immunoproteasome-deficient) transfected with the WT [30Q] or mutant [82Q] ataxin protein, we will test if (a) the presence of a mutant, misfolded protein induces expression of the immunoproteasome, and (b) immunoproteasome provides protection from misfolded proteins. (Aim 3) Hypothesis: Reduced immunoproteasome expression increases the susceptibility to ER stress-induced damage. Using WT and immunoproteasome-deficient cell lines, we will test if immunoproteasome (a) is upregulated under conditions of ER stress, (b) protects from ER stress, and (c) immunoproteasome is involved in activation of the stress- sensitive transcription factor NF-?B. The proposed research brings together a powerful team with expertise in proteasome biology (Ferrington), muscle physiology (Thompson), and age-onset polyglutamine diseases (Orr). This collaboration incorporates techniques in molecular genetics, cell biology, biochemistry, and muscle physiology in pursuing evidence consistent with novel roles for the immunoproteasome in protecting the cell from a variety of stressors. PROJECT NARRATIVE: The proposed work investigates the interplay between specific stressors (Protein Overload and ER Stress) and the immunoproteasome, a specialized proteasome subtype, by defining conditions that induce immunoproteasome expression and testing specific hypotheses regarding immunoproteasomes role in responding to cellular stress. The approach is to use knock-out mice lacking two (lmp7-/-/mecl-1-/-, L7M1) catalytic subunits of the immunoproteasome and conditional SCA1 transgenic mice expressing either the wildtype [30Q] or the mutant [82Q] ataxin-1 protein. Cell lines generated from WT and L7M1 mice and transfected with either the WT [30Q] or mutant [82Q] ataxin protein provide excellent in vitro model systems for testing our hypotheses.
描述(由申请人提供):蛋白酶体通过调节促进细胞存活的信号转导(即,NF-?B)和降解潜在的细胞毒性蛋白(即,缺陷核糖体产物或DRiP)。拟议的工作调查特定的压力(蛋白质过载和ER压力)和免疫蛋白酶体之间的相互作用,通过定义诱导免疫蛋白酶体表达的条件和测试有关免疫蛋白酶体在响应细胞应激中的作用的特定假设。虽然它在产生用于抗原递呈的免疫原性肽中的作用已经明确,但免疫蛋白酶体亚基在非炎症免疫特权组织(例如视网膜和大脑)中的表达意味着其他非免疫功能是可能的。值得注意的是,患病视网膜和大脑中免疫蛋白酶体的上调表明它对诱导应激和损伤的挑战做出反应。核心假设是免疫蛋白酶体是细胞对应激反应的关键组成部分。我们已经做出了几个预测,可以使用我们实验室和我们合作者的实验室已经熟悉的技术和策略进行实验测试,使用缺乏免疫蛋白酶体的两个(lmp 7-/-/mecl-1-/-,L7 M1)催化亚基的敲除小鼠和表达WT [30 Q]或突变[82 Q]共济失调蛋白-1蛋白的条件性SCA 1转基因小鼠。从WT和L7 M1小鼠产生并用WT [30 Q]或突变型[82 Q]共济失调蛋白转染的细胞系为测试我们的假设提供了极好的体外模型系统。(Aim 1)假设:免疫蛋白酶体是有效的肌肉重塑所必需的。将通过后肢减重WT和L7 M1小鼠诱导肌肉重塑,以测试免疫蛋白酶体是否(a)在肌肉重塑期间帮助维持肌肉功能,(B)提供免受细胞损伤的保护,以及(c)直接参与肌肉重塑。(Aim 2)假设:免疫蛋白酶体有助于保护细胞免受错误折叠蛋白质的毒性作用。使用条件性SCA 1转基因小鼠和用WT [30 Q]或突变型[82 Q]共济失调蛋白转染的培养细胞(WT和免疫蛋白酶体缺陷型),我们将测试(a)突变型错误折叠蛋白的存在是否诱导免疫蛋白酶体的表达,以及(B)免疫蛋白酶体是否提供对错误折叠蛋白的保护。(Aim 3)假说:免疫蛋白酶体表达减少增加了对ER应激诱导的损伤的易感性。使用WT和免疫蛋白酶体缺陷细胞系,我们将测试免疫蛋白酶体(a)是否在ER应激条件下上调,(B)是否保护免受ER应激,以及(c)免疫蛋白酶体是否参与应激敏感性转录因子NF-?B。拟议的研究汇集了一个强大的团队,他们在蛋白酶体生物学(Ferrington),肌肉生理学(Thompson)和年龄发作性多聚谷氨酰胺疾病(Orr)方面具有专业知识。这项合作结合了分子遗传学,细胞生物学,生物化学和肌肉生理学的技术,以寻求与免疫蛋白酶体在保护细胞免受各种应激源中的新作用一致的证据。项目叙述:拟议的工作调查之间的相互作用特定的压力(蛋白质过载和ER应力)和免疫蛋白酶体,一个专门的蛋白酶体亚型,通过定义诱导免疫蛋白酶体表达的条件和测试特定的假设免疫蛋白酶体的作用,在响应细胞应激。该方法是使用缺乏免疫蛋白酶体的两个(lmp 7-/-/mecl-1-/-,L7 M1)催化亚基的敲除小鼠和表达野生型[30 Q]或突变型[82 Q]共济失调蛋白-1蛋白的条件性SCA 1转基因小鼠。从WT和L7 M1小鼠产生并用WT [30 Q]或突变型[82 Q]共济失调蛋白转染的细胞系为测试我们的假设提供了极好的体外模型系统。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Deborah Ann Ferrington其他文献
Deborah Ann Ferrington的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Deborah Ann Ferrington', 18)}}的其他基金
Deciphering the mechanisms associated with high-risk AMD genotypes for ARMS2/HTRA1 andComplement Factor H
破译与 ARMS2/HTRA1 和补体因子 H 的高风险 AMD 基因型相关的机制
- 批准号:
10581822 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Deciphering the mechanisms associated with high-risk AMD genotypes for ARMS2/HTRA1 andComplement Factor H
破译与 ARMS2/HTRA1 和补体因子 H 的高风险 AMD 基因型相关的机制
- 批准号:
10707245 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Training Grant: Functional Protemics of Aging
培训补助金:衰老的功能蛋白质学
- 批准号:
8850365 - 财政年份:2008
- 资助金额:
$ 14.72万 - 项目类别:
Training Grant: Functional Protemics of Aging
培训补助金:衰老的功能蛋白质学
- 批准号:
8475023 - 财政年份:2008
- 资助金额:
$ 14.72万 - 项目类别:
Training Grant: Functional Protemics of Aging
培训补助金:衰老的功能蛋白质学
- 批准号:
8792316 - 财政年份:2008
- 资助金额:
$ 14.72万 - 项目类别:
Immunoproteasome: A key component of the cellular stress response
免疫蛋白酶体:细胞应激反应的关键组成部分
- 批准号:
7685277 - 财政年份:2008
- 资助金额:
$ 14.72万 - 项目类别:
Proteomics of altered protein in macular degeneration
黄斑变性中蛋白质改变的蛋白质组学
- 批准号:
6833434 - 财政年份:2004
- 资助金额:
$ 14.72万 - 项目类别:
Proteomics of altered protein in macular degeneration
黄斑变性中蛋白质改变的蛋白质组学
- 批准号:
6992685 - 财政年份:2004
- 资助金额:
$ 14.72万 - 项目类别:
Proteomics of altered protein in macular degeneration
黄斑变性中蛋白质改变的蛋白质组学
- 批准号:
6727783 - 财政年份:2004
- 资助金额:
$ 14.72万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 14.72万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 14.72万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 14.72万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 14.72万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:














{{item.name}}会员




